Literature DB >> 31207041

Potential biomarkers of kaposiform lymphangiomatosis.

Michio Ozeki1, Akifumi Nozawa1, Norio Kawamoto1, Akihiro Fujino2, Satoshi Hirakawa3, Toshiyuki Fukao1.   

Abstract

BACKGROUND: Kaposiform lymphangiomatosis (KLA) has recently been distinguished as a novel subtype of generalized lymphatic anomaly (GLA), and is characterized by foci of spindle endothelial cells amid a background of malformed lymphatic channels. The etiology of these diseases remains unknown and diagnosis is confounded by their similar clinical findings. This study aimed to clarify differences in the clinical findings and plasma cytokine profiles of GLA and KLA patients. PROCEDURE: Clinical features data of GLA and KLA patients were obtained from a national survey. Differences in clinical findings, plasma levels of cytokines, and survival were analyzed. Plasma was obtained from healthy controls and GLA and KLA patients. Thirty-six angiogenic and lymphangiogenic factors were evaluated for cytokine concentration.
RESULTS: Twenty-one patients with GLA and 11 with KLA were recruited. Mediastinal masses, hemorrhagic pericardial and pleural effusion, coagulation disorders, and thrombocytopenia were more frequent in KLA than in GLA. KLA had a significantly poorer outcome than GLA (P = 0.044). Soluble VEGFR3, angiopoietin 2, HGF, soluble HER2, tenascin C, and soluble HGFR levels were higher in KLA. Notably, soluble VEGFR3 and angiopoietin 2 levels were approximately 10-fold higher than those of other molecules measured. However, soluble VEGFR1 and soluble TIE2 were lower in KLA than in GLA and the controls.
CONCLUSIONS: Patients with KLA have an unfavorable prognosis and serious symptoms (hemorrhagic pleural effusion and coagulation disorders). Our data indicate that eight angiogenic cytokines might be potential biomarkers of KLA.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  angiogenesis; cytokine; generalized lymphatic anomaly; kaposiform lymphangiomatosis; lymphatic malformation

Mesh:

Substances:

Year:  2019        PMID: 31207041     DOI: 10.1002/pbc.27878

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  6 in total

1.  Sirolimus in the treatment of kaposiform lymphangiomatosis.

Authors:  Jiangyuan Zhou; Kaiying Yang; Siyuan Chen; Yi Ji
Journal:  Orphanet J Rare Dis       Date:  2021-06-08       Impact factor: 4.123

2.  Detection of NRAS mutation in cell-free DNA biological fluids from patients with kaposiform lymphangiomatosis.

Authors:  Michio Ozeki; Yoko Aoki; Akifumi Nozawa; Shiho Yasue; Saori Endo; Yumiko Hori; Kentaro Matsuoka; Tetsuya Niihori; Ryo Funayama; Matsuyuki Shirota; Keiko Nakayama; Toshiyuki Fukao
Journal:  Orphanet J Rare Dis       Date:  2019-09-11       Impact factor: 4.123

Review 3.  Recent Progress in Lymphangioma.

Authors:  Xiaowei Liu; Cheng Cheng; Kai Chen; Yeming Wu; Zhixiang Wu
Journal:  Front Pediatr       Date:  2021-12-15       Impact factor: 3.418

Review 4.  Genetic and Molecular Determinants of Lymphatic Malformations: Potential Targets for Therapy.

Authors:  Su Yeon Lee; Emma Grace Loll; Abd-Elrahman Said Hassan; Mingyu Cheng; Aijun Wang; Diana Lee Farmer
Journal:  J Dev Biol       Date:  2022-02-08

Review 5.  Osteopathy in Complex Lymphatic Anomalies.

Authors:  Ernesto Solorzano; Andrew L Alejo; Hope C Ball; Joseph Magoline; Yusuf Khalil; Michael Kelly; Fayez F Safadi
Journal:  Int J Mol Sci       Date:  2022-07-26       Impact factor: 6.208

Review 6.  A Primer on a Comprehensive Genetic Approach to Vascular Anomalies.

Authors:  Alexandra J Borst; Taizo A Nakano; Francine Blei; Denise M Adams; Jessica Duis
Journal:  Front Pediatr       Date:  2020-10-19       Impact factor: 3.418

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.